AI-generated summary
The authors report a randomised controlled trial of 31 adults with melasma in Moscow comparing picosecond Alexandrite laser alone with the same laser plus the injectable NCTF 135 HA. The combined group showed larger reported reductions in pigmentation and erythema and a lower recurrence rate at two months. The authors note the small sample and short follow-up mean the findings need confirmation in larger, longer studies.
- Participants
- 31
- Who or what was studied
- Adults with melasma (27 women and 4 men aged 32 to 61 years) treated in a clinical dermatology setting in Moscow, Russia, in 2023
- Limits stated in the abstract
- The authors state the small sample size and short follow-up period mean the findings need confirmation in longer studies with more extensive and diverse populations.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Sample size. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.